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One of the most exciting developments in recent cancer treatment has been the move away from crude cytotoxic agents toward 
drugs that inhibit specific targets in specific cellular pathways. One assumption of this strategy is that maintenance of human 
cancers is dependent upon a limited cadre of therapeutically tractable oncogenic lesions. In this issue of Cancer Cell, an intrigu-
ing paper from Sharma et al. endorses this approach by showing that evolution appears to be working for us. They show that 
an innate asymmetry in the dynamics of intracellular signaling biases pathway inhibition in favor of cell death. This bias may 
significantly potentiate targeted cancer therapies.Intrinsic tumor suppression pathways 
are innate, self-defeating programs that 
evolution has attached to those engines 
of cell expansion whose unbridled activi-
ties would otherwise constitute severe 
neoplastic risk (Lowe et al., 2004). Early 
examples included the unexpected pro-
pensity for activated RAS to induce growth 
arrest and the equally paradoxical procliv-
ity of MYC to drive apoptosis. Such obser-
vations are now understood as examples 
of how the mitogenic actions of individual 
oncoproteins can be exploited by the cell 
only when their inherent growth-inhibi-
tory properties are quelled by collateral 
signals. In the classical paradigm of onco-
gene cooperation, such obligate collateral 
signals are provided by the collaborat-
ing oncogene: hence, each oncogenic 
lesion is dependent on the properties of 
the other for its oncogenic potential to be 
manifest. Thus, the tumor phenotype is an 
emergent property of oncogenic lesions 
acting in concert (Evan and Littlewood, 
1998)—something a geneticist might term 
“synthetic viability” (Figure 1A).
Such observations offered the earli-
est clue that tumor cells might be preter-
naturally dependent for their survival upon 
the aberrant signaling networks that drive 
them, by suggesting that cutting individual 
oncogenic cords within the tumor ensem-
ble can expose the latent intrinsic tumor 
suppression pathways directed by any 
remaining oncogenic lesions. On the other 
hand, since oncogenes harbor the seeds 
of their own destruction, such ideas also cancer cell November 2006 raised the disturbing counter-possibility 
that inactivation of individual oncogenes 
might actually accentuate tumor growth 
by staunching the associated intrinsic 
tumor suppressor pathway. Only with the 
advent of reversibly switchable transgenic 
mouse cancer models, in which the activi-
ties of a specific oncogene targeted to a 
specific tissue can be toggled on and off 
at will, could the net consequences of 
acute oncogene ablation be directly test-
ed in vivo. Such animals are, in essence, 
genetic surrogates for targeted drugs, 
which can be used to establish the extent 
to which maintenance of experimental 
tumors remains dependent upon the onco-
genic mutations that drove their evolution, 
and what the nature of that dependency 
might be. Such in vivo studies indicated 
that deactivation of pivotal oncogenic 
mutations typically triggered profound 
tumor apoptosis that would frequently 
(Chin et al., 1999; Felsher and Bishop, 
1999; Fisher et al., 2001; Pelengaris et al., 
1999, 2002), but not always (Boxer et al., 
2004), lead to marked tumor regression. 
Even though such regression was often 
superseded by the emergence of resistant 
clones, such studies confirmed, in prin-
ciple, the idea that tumor cells acquire de 
novo a dependence upon the lesions that 
drive and maintain them. With the advent 
of targeted cancer therapies, it has finally 
become possible to explore this idea in 
human cancers in vivo, and the successful 
treatment of CML with Gleevec is the post-
er child for the notion that acquired depen-dency on oncogenic mutations holds for 
spontaneously occurring human cancers. 
Naysayers may point to the fact that resis-
tant clones eventually cause relapse of 
Gleevec-treated patients. However, even 
here the news is good: the great major-
ity of relapses involve resistant mutations 
in the ABL kinase rather than wholesale 
replacement of ABL by a newly evolved 
oncogenic edifice (Shah and Sawyers, 
2003). This suggests that dependence 
upon ABL is, indeed, profound and that, 
notwithstanding the genomic instability 
that characterizes the accelerated phase 
of CML, room for evolutionary maneuver 
by surviving tumor cells is extremely con-
strained.
Why should tumor cells acquire a 
dependence upon their oncogenic muta-
tions? The answer seems fairly straight-
forward in situations where an oncogenic 
mutation confers survival properties on 
the cell—for example, overexpression of 
BCL-2/BCL-xL, or constitutive signaling 
through survival factors receptors and 
their intracellular transducers. In such 
cases, removal of the constitutive survival 
signal exposes the targeted tumor cell to 
the full onslaught of preexisting proapop-
totic flux rife in cancers—hypoxic and 
nutrient-poor microenvironments, internal 
havoc wrought of genotoxic injuries and 
aberrant protein folding, and the continu-
ous pumping of apoptotic pathways by 
proproliferative mutations like activated 
MYC and E2F or loss of RB. By contrast, 
the dependence that tumor cells exhibit for 345
	 p r e v i e w soncogenic mutations that drive their prolif-
eration is more unexpected and nuanced 
since, intuitively, inhibition of such lesions 346 might be expected to elicit mere tumor 
stasis rather than regression—a less 
happy therapeutic outcome. In part, the 
dependence of tumor cells on their mito-
genic lesions appears to be due to the 
fact that, in addition to driving tumor cell 
proliferation, most such lesions also exert 
protean influences on multiple aspects of 
tumor maintenance. Thus, mutations that 
drive ineluctable cell proliferation typically 
suppress differentiation. Consequently, 
pulling the proliferative plug can often re-
engage spontaneous resumption of that 
cell’s terminal differentiation program, thus 
permanently expelling that tumor cell from 
the proliferative compartment. In addi-
tion, prototypical mitogenic oncogenes 
like RAS and MYC have been shown to 
buttress many diverse attributes required 
for maintenance of established tumors. 
In addition to driving the cell cycle, they 
promote cell growth, nutrient utilization, 
metabolism, angiogenesis, motility, and 
invasion. Consequently, their deactiva-
tion triggers widespread collapse of both 
cancer cell infrastructure and tumor tissue 
superstructure (Figure 1B).
Nonetheless, such dependencies 
cannot be the whole explanation because 
oncogene dependence is also observed in 
vitro, where nutrients, oxygen, mitogens, 
and survival factors are all abundant, and 
any impact of stromal cells is moot. Hence 
the importance of an enthralling paper by 
Settleman and colleagues (Sharma et al., 
2006, this issue of Cancer Cell), which 
suggests that acquired oncogene depen-
dence arises, at least at the intracellular 
level, from an inherent asymmetry in atten-
uation of intracellular signal pathways. In 
so doing, they have conflated the osten-
sibly disparate phenomena of oncogene 
addiction and intrinsic tumor suppression, 
and also added a subtle twist that could 
have important implications for the tim-
ing and delivery of targeted anticancer Figure 1. The anatomy of acquired oncogene dependence
a: Simplified scheme for oncogene interdependence. Interdependence of two oncogenic mutations 
arises because each counteracts the intrinsic tumor suppressive property of the other. In this example, 
the intrinsic apoptotic program of oNC1 is mitigated by the antiapoptotic actions of oNC2, while the 
cytostatic activity of oNC2 is overcome by the mitogenic actions of oNC1. An example of this particular 
class of oncogene interdependence is the cooperation between myc and bcl-2.
B: Immediate and delayed effects of oncokinase inhibition. Ba: maintenance of the established tumor 
requires continuous oncogene activity to sustain both tumor superstructure (e.g., tumor blood supply 
and stromal interactions) and tumor cell infrastructure (e.g., belaying terminal differentiation, sustaining 
nutrient use, curbing intrinsic tumor suppressor pathways leading to death or senescence). The mecha-
nisms shown are intended to be illustrative, not prescriptive or proscriptive. Bb: Acute oncogene inhibition 
leads to attenuation of all of these programs. However, the greater persistence of intrinsic tumor sup-
pression pathways (apoptosis and, perhaps, senescence) means that these dominate the early stage 
of targeted therapy. Bc: At later times, these intrinsic tumor suppressor programs have also attenuated. 
However, collapse of tumor vasculature, failure of nutrient flux and onset of tumor cell differentiation 
maintains the process of tumor regression. At this point, residual tumor cells might escape therapeutic 
extinction by a variety of mechanisms, including evolution of alternative angiogenic mechanisms, failure 
to differentiate, activation of nutrient uptake, or autophagy.therapies. Oncogenic tyrosine kinases, 
like other dominant oncogenes such as 
RAS and MYC, sit at the apex of multi-
ple downstream signaling pathways that 
exert various biological effects depending 
upon cell type and context. While some of 
these efferent signals are mitogenic, oth-
ers engage intrinsic tumor suppression 
pathways that curb oncogenic potential, 
in part by promoting apoptosis. Using sev-
eral independent in vitro tumor cell mod-
els, driven variously by BCR-ABL, EGFR, 
and SRC tyrosine kinases, Sharma et al. 
show that abrupt oncokinase deactiva-
tion/inhibition triggers rapid attenuation 
of signals passing through the down-
stream prosurvival effectors AKT, STAT5, 
and ERK1/2, abruptly pulling the plug on 
apoptosis protection. By contrast, attenu-
ation of collateral proapoptotic MAPK 
signals generated by the same oncogenic 
kinases is far slower, an innate asymmetry 
in signal persistence that appears to be 
a consequence of the differential rates at 
which the antagonistic actions of onco-
genic kinases and okadaic acid-sensi-
tive phosphatases attack their targets. 
The net effect of this innate asymmetry 
in signal attenuation is that acute inhibi-
tion of oncokinases transiently exposes 
the affected cell to the unmitigated force 
of intrinsic apoptotic tumor suppression. 
The fact that this asymmetry is conserved 
among three very different tyrosine kinas-
es intimates that it may represent a gen-
erally applicable affectation that evolution 
favors as a means to rein in the oncogenic 
potential of signaling molecules. Indeed, 
concurrent activation of both pro- and 
antiapoptotic signals through differing 
downstream effector pathways has been 
previously observed with activated RAS 
(Kauffmann-Zeh et al., 1997), and it is 
quite possible that the potent proapoptotic 
signals elicited by MYC and E2Fs share 
similar temporal dominance over their 
mitogenic siblings.
The proapoptotic signal that Sharma 
et al. identify arises from differential 
decay rates of signals following acute 
oncokinase inhibition. By nature, this is 
short lived. Does this mean that drugs, 
too, will only exert their therapeutic effect 
during a small window after delivery? It 
seems unlikely that such a transient burst 
of apoptosis would be alone sufficient to 
eradicate an established tumor, given that 
tumor cell apoptosis is likely to be modi-
fied by other, antiapoptotic lesions within 
the tumor cell, and drug penetration of 
solid tumors may be quite slow. As already 
discussed, however, asymmetry in signal cancer cell November 2006
	 p r e v i e w sdecay is not the only mechanism under-
lying acquired oncogene dependence, 
and engaging these other mechanisms 
may require longer-term drug exposure 
(Figure 1Bc). Hence, it remains to be seen 
whether a “short, sharp shock” or “staying 
the course” proves the best strategy for 
drug delivery.
More generally, the important and 
fascinating observations of Sharma et 
al. underscore once again (as if this 
were even necessary) the critical impor-
tance of identifying which of the legion of 
mutations in human cancers is respon-
sible for maintenance of the established 
tumor. Tumors accumulate much muta-
tional clutter—bottlenecks that once 
passed are thenceforth irrelevant for 
further tumor maintenance, collateral 
havoc borne of telomere erosion, back-
ground noise that clones out with the 
tumor, bystanders swept up by neigh-
boring amplifications or deletions, and 
weakly advantageous traits contingent 
upon the platform of oncogenic engines cancer cell November 2006 
Over the past two decades, the devel-
opment of improved mouse models for 
human cancers has made important 
contributions to our understanding of 
this set of diseases. By engineering 
mice to contain specific genetic lesions 
found in human cancers, it has been 
possible to address the causal relation-
ship between individual genes and the 
disease phenotype. Furthermore, mice 
that develop malignancies that faith-
fully recapitulate their human counter-
parts provide—at least in theory—more 
appropriate physiological systems in 
which to test candidate antineoplastic 
drugs. Indeed, an array of mouse mod-
els now exists in which the modulation of 
mILC-ing the mouse 
lobular carcinoma
Mouse models that faithfully recapitulate
tumorigenesis and testing potential antic
model that mimics multiple features of in
cancer for which no mouse model curre
loss and tumor initiation and metastasis 
E-cadherin as well as the molecular undethat buttress tumor maintenance. The 
real trick is to work out who is pulling 
the levers and pressing the buttons that 
keep the established tumor going and 
not get sidetracked into endless cata-
loging of epiphenomena. Sharma et al. 
show that evolution has handed us a 
great gift for cancer treatment—so long 
as we stay on target.
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present with a histologically distinct form 
of the disease, termed invasive lobular 
carcinoma (ILC). Beyond their morpho-
logic distinctions, these tumor types 
also differ at the molecular level. One 
particularly prominent difference is that 
ILCs typically lose expression of the cell 
adhesion molecule E-cadherin, whereas 
IDCs retain its expression. ILC and IDC 
also exhibit differences in their biological 
behavior, including their patterns of meta-
static spread. To date, however, there has 
been no mouse model that recapitulates 
the unique features of ILC, a fact that has 
impeded research into this disease.
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